ABSTRACT
The objective of this study was to use network analysis to identify subtypes of relapsing-remitting multiple sclerosis subjects based on their cumulative signs and symptoms. We reviewed the electronic medical records of 120 subjects with relapsing-remitting multiple sclerosis and recorded signs and symptoms. Signs and symptoms were mapped to a neuroontology and then collapsed into 16 superclasses by subsumption and normalized. Bipartite (subject-feature) and unipartite (subject-subject) network graphs were created using Gephi. Degree and weighted degree were calculated for each node. Graphs were partitioned into communities using the modularity score. Feature maps were used to visualize differences in features by the community. Network analysis of the unipartite graph yielded a higher modularity score (0.49) than the bipartite graph (0.247). Network analysis can partition multiple sclerosis subjects into communities based on signs and symptoms. Communities of subjects with predominant motor, sensory, pain, fatigue, cognitive, behavior, and fatigue features were found. Larger datasets and additional partitioning algorithms are needed to confirm these results and elucidate their clinical significance.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
MDC acknowledges research funding from the Department of Veterans Affairs (BLR\&D Merit Award BX000467) and prior support from Biogen. DCW II acknowledges research funding support from the Mary K. Finley Endowment at the Missouri University of Science and Technology.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of the University of Illinois at Chicago
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
